← QUEST DIAGNOSTICS INC (DGX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
QUEST DIAGNOSTICS INC (DGX)
Services-Medical Laboratories · market cap $26.1B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-22
Earnings
Pipeline
0
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Quest Diagnostics (DGX) is a Fortune 500 clinical laboratory services company with ~65,000 employees, operating primarily in the US with additional presence in Puerto Rico, Mexico, and Brazil. The company generates ~$11B in annual revenue with consistent profitability, carries $5.3B in net debt against $393M cash, and trades at ~$208 with a $23B market cap. A curious data anomaly flags Carboplatin (a generic chemotherapy agent) in a Phase 2 trial for Ovarian Neoplasms as its 'lead asset,' which almost certainly reflects a pipeline database artifact rather than a core strategic initiative for a diagnostics company.
The catalyst path
- 2026-10-22Earningsimp 5/10
Pipeline
No pipeline data.
Price & technical context
3-month
+7.1%
6-month
+16.9%
12-month
+21.3%
52-wk range
$173.49–$247.45
vs 50-day MA
-2.8%
vs 200-day MA
+12.3%
Realized vol
23.7%
Max drawdown
-11.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DGX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.